论文部分内容阅读
目的:研究甲胎蛋白异质体在肝癌早期诊断的应用价值。方法:研究对象选择为我院2013年12月-2014年12月收治的肝脏疾病患者300例,为了便于研究,将其分为甲、乙两组,其中甲组(170例)是原发性肝癌患者,乙组(130例)是慢性肝病患者,应用电化学发光免疫分析法和微量离心柱法对其血清中的甲胎蛋白和甲胎蛋白异质体进行检测,比较两组检测情况。结果:甲组患者的甲胎蛋白异质体中位水平以及敏感性皆比乙组患者高,组间比较,差异具有统计学意义(P<0.05)。同时,甲胎蛋白异质体的中位水平以及阳性率随着肝癌患者的病情分期以及肿瘤的增大而上升。结论:甲胎蛋白异质体在肝癌早期诊断的应用价值较好。
Objective: To investigate the value of alpha-fetoprotein heterogeneity in the early diagnosis of liver cancer. Methods: The study object was selected from 300 patients with liver diseases admitted from December 2013 to December 2014 in our hospital. To facilitate the study, 300 cases were divided into two groups, Group A (170 cases) were primary Patients with liver cancer, Group B (130 cases) were patients with chronic liver disease. The levels of alpha-fetoprotein and alpha-fetoprotein in serum were detected by electrochemiluminescence immunoassay and micro-centrifugation column method. Results: The median level of alpha-fetoprotein heterozygote and its sensitivity in Group A patients were higher than those in Group B patients. The difference was statistically significant (P <0.05). At the same time, the median level and the positive rate of alpha-fetoprotein heterogeneity increased with the staging and the tumor size of HCC patients. Conclusion: The application of alpha-fetoprotein heterogeneity in the early diagnosis of liver cancer is better.